Alpine Immune Sciences Inc expected to post a loss of 34 cents a share - Earnings Preview

Alpine Immune Sciences

15/03/2024 21:02

* Alpine Immune Sciences Inc  ALPN.OQ   ALPN.O  is expected
to show a rise in quarterly revenue when it reports  results on
March 18 for the period ending December 31 2023
    * The Seattle Washington-based  company is expected to
report a
228.0% increase in revenue to $9.104 million from $2.78 million
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Alpine Immune Sciences
Inc is
for a loss of 34 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Alpine
Immune
Sciences Inc is $33.00​, below​ its last closing price
of $35.89. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.30       -0.33      -0.24     Beat    28.2
 Jun. 30 2023  -0.36       -0.37      -0.27     Beat    27.9
 Mar. 31 2023  -0.37       -0.37      -0.28     Beat    24.4​
 Dec. 31 2022              -0.27      -0.41     Missed  -53
 ​​Sep.        -0.02       -0.10      -0.42     Missed  -309.8
 30 2022                                                
 Jun. 30 2022  -0.46       -0.39      -0.60     Missed  -52.9​
 Mar. 31 2022  -0.27       -0.19      -0.25     Missed  -33.3
 Dec. 31 2021  -0.43       -0.30      -0.52     Missed  -70.5
 This summary was machine generated March 15 at 21:02 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)